Edgewise Therapeutics (EWTX) Operating Expenses (2020 - 2026)

For the trailing twelve months through Jun 30, 2026, Operating Expenses at Edgewise Therapeutics was $218.9 million, up 25.4% year-over-year; for FY2025, it was $191.41 million, up 20.5% from FY2024.

• Annual Operating Expenses has increased for five consecutive years, with a five-year compound annual growth rate of 61.9% (FY2020 to FY2025).
• In prior years, Edgewise Therapeutics' Operating Expenses was $158.83 million in FY2024 (+38.9%), $114.36 million in FY2023 (+59.6%), $71.66 million in FY2022 (+65.8%) and $43.22 million in FY2021 (+151.4%).
• The Q2 2026 figure stands as the highest quarterly Operating Expenses in data going back to Q1 2020.
• On a year-over-year basis, Operating Expenses has increased in each of the last 22 quarters, with growth averaging 27.2% over the last eight quarters.
• Across the past five years, year-over-year growth in Operating Expenses ran from 11.8% in Q2 2025 to 258.9% in Q3 2021.
• According to Business Quant data, Operating Expenses for the three prior quarters was $54.12 million (Q1 2026), $55.98 million (Q4 2025) and $46.86 million (Q3 2025).